Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.
Roche's combination of its PD-L1 inhibitor Tecentriq with chemotherapy in first-line treatment of non-squamous non-small cell lung cancer showed a significant 21% reduction in risk of death compared with chemo alone, but the results still may not be enough to cut it commercially.
Detailed results of the IMpower130 study were presented at the European Society for Medical Oncology (ESMO) meeting in Munich Oct. 22, following a positive top-line release in May
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
